AGA
ATRA icon

Altrinsic Global Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Altrinsic Global Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,000
Closed -$1.58M – 49
2021
Q4 		$1.58M Hold
4,000
– – 0.05% 63
2021
Q3 		$1.79M Buy
4,000
+400
+11% +$143K 0.05% 66
2021
Q2 		$1.4M Buy
3,600
+400
+13% +$143K 0.04% 69
2021
Q1 		$1.15M Hold
3,200
– – 0.04% 74
2020
Q4 		$1.57M Hold
3,200
– – 0.05% 68
2020
Q3 		$1.04M Buy
3,200
+1,200
+60% +$409K 0.04% 71
2020
Q2 		$729K Buy
+2,000
New +$505K 0.03% 74

Other funds holding ATRA

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Altrinsic Global Advisors's ATRA Position: Q1 2022 in Review

Altrinsic Global Advisors sold out of Atara Biotherapeutics (ATRA) in Q1 2022, closing a stake of 4,000 shares — an estimated $1.58M sold.

Altrinsic Global Advisors first reported a position in ATRA in Q2 2020 and held it in 7 quarters. The position peaked at $1.79M in Q3 2021. 144 funds tracked by Wall St. Rank hold ATRA as of Q1 2022.

  • Altrinsic Global Advisors reported no remaining Atara Biotherapeutics position as of Q1 2022 after selling out during the quarter.
  • Altrinsic Global Advisors sold 4,000 Atara Biotherapeutics shares in Q1 2022, an estimated $1.58M.
  • Altrinsic Global Advisors first reported a position in Atara Biotherapeutics in Q2 2020 and held it in 7 quarters.
  • Altrinsic Global Advisors's Atara Biotherapeutics position peaked at $1.79M in Q3 2021.
  • 144 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2022.

Based on Altrinsic Global Advisors's 13F filing for Q1 2022, filed 16 May 2022.